Lazard Asset Management
GBIO

Lazard Asset Management’s Generation Bio GBIO Stock Holding History

Lazard Asset Management’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-306
Closed -$4K – 2167
2023
Q4 		$4K Sell
306
-19
-6% -$331 ﹤0.01% 2128
2023
Q3 		$12K Buy
325
+17
+6% +$805 ﹤0.01% 2135
2023
Q2 		$16K Buy
308
+12
+4% +$551 ﹤0.01% 2137
2023
Q1 		$12K Buy
296
+59
+25% +$2.85K ﹤0.01% 2112
2022
Q4 		$9K Buy
+237
New +$12.4K ﹤0.01% 2208

Other funds holding GBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Lazard Asset Management's GBIO Position: Q1 2024 in Review

Lazard Asset Management sold out of Generation Bio (GBIO) in Q1 2024, closing a stake of 306 shares — an estimated $4K sold.

Lazard Asset Management first reported a position in GBIO in Q4 2022 and held it in 5 quarters. The position peaked at $16K in Q2 2023. 74 funds tracked by Wall St. Rank hold GBIO as of Q1 2024.

  • Lazard Asset Management reported no remaining Generation Bio position as of Q1 2024 after selling out during the quarter.
  • Lazard Asset Management sold 306 Generation Bio shares in Q1 2024, an estimated $4K.
  • Lazard Asset Management first reported a position in Generation Bio in Q4 2022 and held it in 5 quarters.
  • Lazard Asset Management's Generation Bio position peaked at $16K in Q2 2023.
  • 74 funds tracked by Wall St. Rank held Generation Bio as of Q1 2024.

Based on Lazard Asset Management's 13F filing for Q1 2024, filed 14 May 2024.